Janchor Partners

Eden Brew is a food and beverage company focused on producing animal-free and precision-fermented milk and dairy products. The company aims to provide an environmentally sustainable alternative to traditional cow's milk, offering dairy products that are vegan-friendly and lactose-free. Using precision fermentation technology, Eden Brew creates milk that contains nature-identical proteins and nutrients, allowing consumers to enjoy the taste and nutritional benefits of dairy without the environmental impact associated with conventional dairy farming.

FPL Technologies Pvt. Ltd., founded in 2019 and headquartered in Mumbai, India, focuses on providing innovative financial solutions for a digitally savvy younger population. The company has developed a proprietary technology platform that aims to enhance the credit card experience, capitalizing on the growing demand for consumption credit in India. With the recent surge in digital payment adoption, FPL recognizes the need for a more user-friendly approach to credit management. Their flagship product, the One Score app, launched to help users check and understand their credit scores, offers a secure and straightforward way to manage credit behavior. By integrating an intuitive mobile application with their credit card services, FPL Technologies seeks to meet the evolving needs of millennials and improve their overall financial literacy and credit experience.

MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company is focused on licensing, developing, and commercializing innovative therapies aimed at addressing significant unmet medical needs primarily in Greater China and other Asia Pacific markets. Its portfolio includes eight clinical-stage drug candidates targeting various conditions, including oncology, immunology, cardio-renal disease, and infectious diseases. By integrating discovery, clinical development, commercialization, and manufacturing processes, Everest Medicines seeks to deliver potentially transformative pharmaceutical therapies that improve patient outcomes. The company aims to partner with leading global pharmaceutical firms to bring its products to market, leveraging its team's expertise in clinical development, regulatory affairs, and operations.

RemeGen, Ltd. is a biopharmaceutical company based in Yantai, Shandong Province, China, focused on addressing unmet medical needs for patients with life-threatening conditions. The company specializes in the research, development, manufacturing, and commercialization of innovative biologics, particularly monoclonal antibodies and antibody-drug conjugates. RemeGen's leading products include Telitacicept, aimed at treating systemic lupus erythematosus, and Disitamab Vedotin, designed for various cancers. The company’s therapeutic offerings target significant health issues, including autoimmune diseases, oncology, and ophthalmology. With operations in both China and the United States, RemeGen primarily generates its revenue from the Chinese market.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

Alphamab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative therapeutics for cancer treatment. The company utilizes proprietary platforms in bispecific antibodies and protein engineering to create a robust pipeline of oncology and immunology products. Key candidates in development include KN046, a bispecific monoclonal antibody immune checkpoint inhibitor targeting PD-L1 and CTLA-4, and KN026, an advanced anti-HER2 bispecific antibody. Additionally, KN019, an immunosuppressant fusion protein, and KN035, a PD-L1 inhibitor, are also progressing through clinical trials, addressing various solid tumors and autoimmune conditions. Founded in 2008, Alphamab Oncology is committed to developing next-generation therapies to meet global medical needs in oncology.

FirstMeridian is a human resources investment platform that leverages technology and innovation to provide comprehensive HR services. The company specializes in general and professional staffing, permanent recruitment, managed services, and HR technology and automation. By focusing on these areas, FirstMeridian aims to enhance economic opportunities for the workforce, ultimately transforming lives through improved employment solutions.